265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details

臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97

diseases per page:

Showing 1 to 10 of 116 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05088460 (ClinicalTrials.gov)	January 24, 2022	12/10/2021	A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Pati ...	A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Tre ...	Familial Partial Lipodystrophy;Metabolic Abnormalities	Drug: REGN4461;Drug: Matching Placebo	Regeneron Pharmaceuticals	NULL	Not yet recruiting	18 Years	N/A	All	40	Phase 2	NULL
2	NCT05164341 (ClinicalTrials.gov)	December 2021	11/11/2021	A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the S ...	A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the S ...	Partial Lipodystrophy	Drug: metreleptin;Drug: Placebo	Amryt Pharma	NULL	Not yet recruiting	5 Years	N/A	All	80	Phase 3	NULL
3	NCT04710056 (ClinicalTrials.gov)	June 2021	13/1/2021	Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy ...		Generalized Lipodystrophy;Partial Lipodystrophy;Monogenic Obesity Due to LEP or LEPR Loss of Functio ...	Drug: REGN4461	Regeneron Pharmaceuticals	NULL	Available						NULL
4	NCT04860063 (ClinicalTrials.gov)	April 2021	17/4/2021	Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Th ...	Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Th ...	Metabolic Syndrome;HIV-1-infection;Glucose Intolerance;Dyslipidemias;Lipodystrophy;Lipoatrophy	Drug: Berberine;Drug: Placebo	Hospital Civil de Guadalajara	NULL	Not yet recruiting	18 Years	60 Years	All	40	Phase 3	NULL
5	NCT04903847 (ClinicalTrials.gov)	February 2, 2021	9/10/2020	Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Ten ...	Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compare ...	Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;Obesity	Drug: Dolutegravir /Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine /Lamivudine/Tenofovi ...	Thomas Benfield	NULL	Recruiting	18 Years	N/A	All	126	Phase 4	Denmark
6	NCT04517253 (ClinicalTrials.gov)	October 27, 2020	17/8/2020	A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAV ...	A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adu ...	Nakajo-Nishimura Syndrome;Chronic Atypical Neutrophilic Dermatosis With Lipodystrophyand Elevated Te ...	Drug: Baricitinib	Eli Lilly and Company	NULL	Active, not recruiting	6 Months	N/A	All	5	Phase 2/Phase 3	Japan
7	NCT04904406 (ClinicalTrials.gov)	October 22, 2020	9/10/2020	Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-i ...	Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued ...	Hiv;HIV Infections;HIV Cardiomyopathy;Weight Change, Body;HIV Lipodystrophy;Cardiovascular Diseases	Drug: Dolutegravir / Lamivudine Oral Tablet	Thomas Benfield	NULL	Recruiting	18 Years	N/A	All	95	Phase 4	Denmark
8	NCT04340388 (ClinicalTrials.gov)	September 17, 2020	1/4/2020	Contribution of Dolutegravir to Obesity and Cardiovascular Disease	Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Person ...	HIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnor ...	Drug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIV	Augusta University	NULL	Recruiting	18 Years	100 Years	All	30	Phase 4	United States
9	NCT04159415 (ClinicalTrials.gov)	January 7, 2020	7/11/2019	Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy	A Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody ...	Generalized Lipodystrophy	Drug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461	Regeneron Pharmaceuticals	NULL	Active, not recruiting	12 Years	N/A	All	16	Phase 2	United States;Peru;Russian Federation;Turkey
10	NCT04056000 (ClinicalTrials.gov)	September 1, 2019	23/5/2019	Lipodystrophy and Fat Metabolism During Exercise	The Regulation of Fat Metabolism in a Cyclist With Lipodystrophy: a Case Study	Healthy;Lipodystrophy, Familial Partial	Dietary Supplement: Caffeine;Dietary Supplement: High-carbohdyrate breakfast;Behavioral: 60-minutes ...	University of Exeter	NULL	Withdrawn	18 Years	35 Years	Male	0	N/A	United Kingdom

First Previous1 2 3 4 5…12Next Last